The high Aβ42/Aβ40 production ratio is a hallmark of familial Alzheimer’s disease, which can be caused by mutations in the amyloid precursor protein (APP). The C-terminus of Aβ is generated by γ-secretase cleavage within the transmembrane domain of APP (APPTM), a process that is primed by an initial ε-cleavage at either T48 or L49, resulting in subsequent production of Aβ42 or Aβ40, respectively. Here we solve the dimer structures of wild-type APPTM (AAPTM WT) and mutant APPTM (FAD mutants V44M) with solution NMR. The right-handed APPTM helical dimer is mediated by GXXXA motif. From the NMR structural and dynamic data, we show that the V44M and V44A mutations can selectively expose the T48 site by weakening helical hydrogen bonds and increasing hydrogen–deuterium exchange rate (kex). We propose a structural model in which FAD mutations (V44M and V44A) can open the T48 site γ-secretase for the initial ε-cleavage, and consequently shift cleavage preference towards Aβ42.
Amyloid β-peptide (Aβ) is the major component of senile plaques, a pathologic hallmark of Alzheimer’s disease (AD)1. Amyloid precursor protein (APP) is an integral membrane protein with a single transmembrane (TM) domain, which is consecutively cleaved by β- and γ-secretase to generate amyloid beta (Aβ) peptides2. Aβ40 and Aβ42, consisting of 40 and 42 residues, respectively, are the two major isoforms of Aβ in human brains1,3. While Aβ40 is relatively benign, Aβ42 aggregates rapidly into neurotoxic oligomers and fibrils (plaques)4. Aβ42 is not only toxic in neuronal culture5, but also in animal models6. Familial Alzheimer’s disease (FAD) is caused by dominant mutations in genes encoding APP and γ-secretase. FAD is biochemically characterized by the increased ratio of Aβ42 over Aβ40 (refs 7, 8), implicating the crucial role of Aβ42 in AD pathogenesis. However, the mechanism of how FAD mutations increase Aβ42/Aβ40 remains poorly understood.
The proteolytic cleavage of APP is initiated by β-secretase within the extracellular domain of APP, releasing a C-terminal membrane-anchored fragment of 99 residues (C99)9,10. C99 is further processed by γ-secretase within the TM domain of APP (APPTM) to yield mature Aβ peptides and the APP intracellular domain (AICD)11,12,13. However, the cleavage of APPTM by γ-secretase is not specific, as varying lengths of Aβ peptides have been observed11. Aβ40 is the predominant product, while Aβ42 is generated to a lesser extent4. Another cleavage site, called the ε-cleavage site, has recently been established as the initial C99 cleavage site by γ-secretase, which generates Aβ48 or Aβ49 and AICD49-99 or AICD50-99, respectively14. Successive proteolysis by the processive carboxypeptidase-like activity of γ-secretase releases tripeptides and tetrapeptides from the C-terminus of Aβ48 and Aβ49. Two production lines are distinguished, one for Aβ40 and the other for Aβ42. Aβ46, Aβ43 and Aβ40 are generated from Aβ49, while Aβ45, Aβ42 and Aβ38 are produced from Aβ48 (ref. 14). Therefore, initial ε-cleavage at residue 48 (T48, γ-secretase cleaving between residues 48 and 49) or 49 (L49, cleaving between 49 and 50) determines whether Aβ42 or Aβ40, respectively, can be produced and can critically influence the Aβ42/40 ratio.
Twelve FAD mutations have been identified within the APPTM7,15,16,17,18,19,20, which contains the ε- and γ-cleavage sites. These FAD mutations contribute to an increased Aβ42/Aβ40 ratio8,21. Using APPTM as the substrate, we have developed a novel γ-secretase assay which reproduces Aβ42/Aβ40 ratios for WT APPTM and FAD mutants22. This suggests that APPTM itself, as a substrate for γ-secretase, mimics the behaviour of the natural substrate C99 and that APPTM plays an important role in determining Aβ42/Aβ40 ratios.
Although ample structural work on APPTM has been published, it remains unclear how FAD mutation within APPTM increase the Aβ42/Aβ40 ratio. Sanders’ group presented the first solution NMR studies of C99 (refs 23, 24), which includes APPTM, and a recent monomer structure relevant for cholesterol binding23. However, the existence of APPTM as a dimer has been supported by numerous studies24,25,26,27,28. Sato et al.27 derived a dimeric structural model for APPTM based on limited constraints from solid-state NMR. Solid-state NMR also revealed both helical and non-helical conformations at the two termini and in the vicinity of the γ-secretase site in APPTM in lipids29. Computational models of APPTM dimers were published by Miyashita et al.30 and more recently by Wang et al.31 Finally, Nadezhddin et al.28 reported the solution NMR structure of APPTM WT as a left-handed dimer, though this model is based on intermolecular NOEs from filtered experiments only and has not been refined with residual dipolar couplings (RDCs).
In this study, to explore the structural mechanism of increased Aβ42/Aβ40 ratio in FAD mutations within APPTM, we use solution NMR spectroscopy to investigate the structure and dynamics of three variants of APPTM, wild type (WT) and two FAD mutants, V44M (French mutation) and V44A (German mutation). Because we have shown APPTM itself is an excellent substrate of γ-secretase and FAD mutations within APPTM produce similar effects on 42/40 ratios as in assays using C99 as the substrate22, our NMR studies of APPTM itself can be directly correlated to the specificity of γ-secretase cleavage and Aβ42/Aβ40 ratios. Here, we show that V44M and V44A significantly alter the structure and dynamics of T48, the ε-cleavage site for Aβ42 production and propose a novel mechanism for increased Aβ42/Aβ40 ratio in FAD.
V44M and V44A cause large CSP at the ε-cleavage site T48
Isotopically labelled APPTM WT V44M were reconstituted in dodecylphosphocholine (DPC) micelles as described in Chen et al.32 and their complete assignments have been achieved with triple resonance experiments and deposited in BioMagResBank (BMRB entry 18,648 and 18,649). The residues are numbered according to Aβ (Supplementary Fig. S1). Figure 1a shows the 15N–1H HSQC spectra of WT and V44M APPTM, with narrow dispersion typical of TM helices. The two spectra have similar peak patterns, suggesting that the V44M mutation does not change the overall fold of APPTM. Large chemical shift perturbations (CSPs) are observed at and near the site of the mutation (residues 44–48), as expected (Fig. 1b). While the largest 15N CSP is at V44M, the largest 1H CSP occurs at T48 (Fig. 1b), whose amide proton chemical shift decreases from 8.14 p.p.m. in WT to 7.93 p.p.m. in the mutant. The ~0.2 p.p.m. CSP indicates significant changes in magnetic environment of T48 amide proton, most likely due to changes in hydrogen bonding. We also have compared the backbone amide chemical shifts of V44A, another FAD mutant, with WT (Fig. 1b). While the largest 15N CSP is at the site of mutation V44A, the largest 1H CSP again occurs at T48 (Fig. 1b). As T48 is the initial recognition site of γ-secretase for the Aβ42 production line (Supplementary Fig. S1)14, such changes in the local conformations of the ε-cleavage site may have important implications for the Aβ42/Aβ40 ratio.
V44M changes local conformations of ε-cleavage sites
To further investigate the detailed structural changes brought about by the V44M mutation, we solved the solution structures of both APPTM WT and V44M dimers, which were based on unambiguous intermolecular NOEs (Fig. 2) and RDCs from two different alignment media (Table 1). The dimerization of APPTM in DPC micelles was confirmed by analytical ultracentrifugation (Supplementary Fig. S2) and supported by numerous previous studies24,25,26,27,28. Unambiguous intermolecular NOEs were determined by a number of chimera NMR samples with selective isotopical labelling (Fig. 2). Because only one set of NMR resonances are observed (Fig. 1a), the structure was calculated as a symmetric dimer. On average, 25.4 (WT) and 25.9 (V44M) constraints per residue were obtained, including 9 intermolecular NOEs for WT and 11 intermolecular NOEs for V44M. An ensemble of 20 structures were calculated from XPLOR-NIH for WT and V44M (for stereo images of superimposed NMR structures, see Supplementary Figs S3 and S4), with backbone and heavy atom pairwise RMSDs at 0.79 and 1.28 Å (WT) and 0.81 and 1.31 Å (V44M), respectively (Table 1). The coordinates and constraints have been deposited in the protein data bank as 2LZ3 (WT) and 2LZ4 (V44M).
Both WT and V44M form right-handed dimers, as in the classical TM dimer of glycophorin A (GpA) (Fig. 3)33. The crossing angle between the two helices is 22° for WT and 33° for V44M. For both APPTM WT and V44M, the GXXXA motif (residues 38–42) mediates the dimer interface (Fig. 3a). In contrast, the GXXXG motifs in APPTM do not have a direct role in dimerization. In addition, the side chains of M35, V39, I45, V46 and L49 provide key hydrophobic interactions at the dimer interface for the WT molecule. There is no hydrogen bond or salt bridge across the dimer interface.
The dimer fold and interface are generally retained in the V44M mutant but the dimerization pattern is altered significantly (Fig. 3b). The GXXXA motif and the side chains of M35, V39 and V46 still mediate dimerization; however, there is a registry shift in hydrophobic side-chain packing towards the C-terminus. I45 and L49 are no longer present at the dimer interface in V44M while T43 and V50 provide new hydrophobic packing for V44M dimerization. While T48 is not at the dimer interface in either structure, V44M mutation relocates L49 away from the dimer interface.
The large CSP in the T48 amide proton led us to more closely examine the helical hydrogen bonds. Overall, the V44M mutation strengthens hydrogen bonding at the N-terminal half of the helix while weakening those at the C-terminal half (Fig. 4). The helical hydrogen bonds involving the ε-cleavage site T48 and L49 amides experience large changes. In the 20 NMR structures, the average distance between the T48 amide proton and the V44 carbonyl oxygen is 2.2±0.2 Å and 3.23±0.14 Å in the WT and V44M mutant, respectively. The average distance between the L49 amide proton and the I45 carbonyl oxygen is 2.3±0.2 Å and 2.8±0.4 Å in WT and V44M, respectively. Thus the helical hydrogen bond involving both T48 and L49 amide protons are both weakened and the effect is much more pronounced for T48 than for L49.
V44M and V44A enhance kex of T48 more than L49
To further probe helical stability and dynamics with residue-specific resolution, we have carried out hydrogen–deuterium (HD) exchange measurements at 298 K (Fig. 5a). Helical core residues between I41 and I47 had no decrease in their signal intensity in HSQC spectra after 30 h in D2O, due to very slow exchange with water, in both WT and V44M (Fig. 5a and Supplementary Fig. S5). Residues V36–V40 display decreasing exchange rates towards the centre of the helix while exchange rates of residues T48–V50 increase towards the C-terminus in both WT and V44M. T48 has an ~4-fold enhancement in HD exchange rate, increasing from 0.009 per h in WT to 0.034 per h in V44M (Figs 4 and 5a), while L49 has an ~2-fold increase (0.028 per h in WT versus 0.05 per h in V44M) (Fig. 5a). Consequently, both initial ε-cleavage sites are destabilized by V44M, but the effect is more significant for T48 than for L49. Titration with paramagnetic relaxation enhancement (PRE) probes demonstrated similar micelle embedment around the ε-cleavage sites in WT and V44M (Supplementary Fig. S6), suggesting the observed changes in HD exchange rates are not due to the differences in micelle embedment.
HD exchange experiment was also carried out for V44A, another FAD mutant. In V44A, T48 has a 4 fold enhancement in kex, increasing from 0.009 per h in WT to 0.036 per h in V44A (Fig. 5a), while L49 has only an ~30% fold increase (0.028 per h in WT versus 0.036 per h in V44M) (Fig. 5a). Such changes in kex may indicate enhanced accessibility of T48 site to ε-cleavage by γ-secretase. Indeed, it has been reported recently that V44A dramatically increase the ratio of AICD49-99/AICD50-99 (ref. 34), where AICD49-99 and AICD50-99 are the product of ε-cleavage at L48 and T49, respectively.
For the first time, we have compared the structure and dynamics of WT APPTM and one of its FAD mutants V44M at atomic resolution. We find that V44M mutation destabilizes the local helical conformation and increases dynamics at the ε-cleavage sites. These changes are especially pronounced for T48, the initial ε-cleavage site for the Aβ42 production, as shown by the large amide proton CSP, lengthening of the helical hydrogen bonds and significantly amplified kex. Similar changes in CSP and HD exchange rate were obtained for V44A, another FAD mutant. These data indicate that T48 is much more prone to undergo helical unwinding in V44M and V44A than WT, suggesting a structural mechanism of how V44M and V44A can increase Aβ42/Aβ40 ratio (Fig. 5b). γ-Secretase first cleaves APPTM endoproteolytically at the ε-sites, at residues T48 or L49 (refs 14, 35, 36), followed by carboxypeptidase-like activity, resulting in two lines of Aβ production: the Aβ42 line (48→45→42→38), and Aβ40 line (49→46→43→40) (Supplementary Fig. S1). For the initial ε-cleavage to occur, the ε-site scissile bonds need to be accessible to the γ-secretase active site and catalytic water, which requires the unraveling of the local helical conformation. Because the T48 and L49 amides are adjacent to the scissile bond carbonyl within the same residue, these amides serve as excellent reporter for the accessibility of the ε-sites. While the V44M and V44A mutations destabilize the local helical conformation of both ε-cleavage sites, the mutations destabilizes the T48 site more than L49 site. The increased accessibility of T48 for ε-cleavage can shift Aβ production towards Aβ42, increasing the Aβ42/Aβ40 ratio. Such increased accessibility of T48 for ε-cleavage will lead to enhanced ε-cleavage at T48 relative to T49. This has been recently demonstrated by Dimitrov et al., who reported a dramatic enhancement in the ratio of AICD49-99/AICD50-99 in V44A and other FAD mutants near the γ-secretase cleavage site34. The proposed mechanistic hypothesis is also consistent with the report that FAD mutations within APP usually increase the Aβ42/Aβ40 ratio by modifying the product line preference of γ-secretase35.
An alternate dimer structure of APPTM WT was reported in early 2012 by Nadezhdin et al.28 This structure was also solved in DPC micelles and exhibited a similar dimer interface as in our structure, with the GXXXA as the dimerization motif. The Nadezhdin structure is significantly different from our structure, as the RDC values used in our structure calculation are not consistent with the Nadezhdin structure (Supplementary Fig. S7). A major difference between our structure and the Nadezhdin structure is that we have a right-handed dimer, while they have a left-handed dimer. Their construct contained an additional 13 residues QKLVFFAEDDVGS to the N-terminus of APPTM, which formed a nascent helix and could contribute to the structural discrepancy. Their dimer structures were built on 6 intermolecular NOEs between methyl groups from filtered experiments only. In contrast, our structures are based upon intermolecular NOEs derived from three differentially labelled NMR chimera samples, in addition to NOEs from filtered experiments (Fig. 2). We used a mixed sample of [U-15N; U-2H] APPTM and unlabelled APPTM to obtain intermolecular NH-methyl NOEs. We also utilized a 1:1 mixture of [U-15N] labelled and [U-13C] labelled sample to yield unambiguous intermolecular NOEs between 15N-H and 13C-H. No RDC data were used in the calculation of the Nadezhdin structure while our structures were refined with RDCs determined in two alignment media, dGpG and stretched gel. RDC values can globally define NH orientations and avoid potential mistakes resulting from the local nature of NOE distance constraints.
A recent NMR structure of C99 has been published which includes APPTM within the sequence23. C99 is known to dimerize through APPTM and is present in both monomer and dimer forms24,31,37. Barrett et al. chose to solve the monomer structure of C99 in lyso-myristoylphosphatidylglycerol (LMPG) micelles and primarily focused on the cholesterol-binding properties of C99. Therefore, the C99 NMR structure represents an alternative functional state for APPTM from our APPTM dimer structure. Interestingly, Barrett et al. showed that one of the GXXXG motifs plays a key role in cholesterol binding, which is consistent with our observation that GXXXG motif is not involved in APPTM dimerization.
APPTM dimerization has been well-established, but the dimerization motif has been controversial. There are three potential dimerization motifs within APPTM: two GXXXG motifs and one GXXXA motif (Supplementary Fig. S1). Several groups provided evidence supporting GXXXG motifs as the key dimerization motif25,27,31,38,39, while the current study, Nadezhdin et al.28 and Gorman et al.26 demonstrated that the GXXXA motif is the single most important motif for dimerization. The differences in the literature are likely due to variations in experimental conditions. Disparate membrane mimetics, for example, the different types of detergent, lipid and membrane system employed, can have dramatic impact on the dimerization mode. Indeed a solid-state NMR study has shown that lipid composition in multi-lamellar vesicle can significantly alter the conformation and dynamics of APPTM29. Recently, Wang et al. published an MD simulation of APPTM dimerization in conjunction with TOXCAT dimerization assay and showed that APPTM may have multiple dimerization modes, in which both GXXXG and GXXXA can mediate dimerization31. Therefore, it is likely that APPTM may dimerize through various motifs under different physiological conditions and for different functions. The presence of cholesterol may induce a dimerization mode more amenable to γ-secretase cleavage, where GXXXA mediates dimerization and GXXXG motifs bind to cholesterol. As the γ-secretase cleavage progresses and the hydrophobicity of APPTM decreases, the dimerization motif may shift towards the N-terminus and be mediated by the GXXXG motifs, facilitating the exit of Aβ from the membrane.
In summary, we have shown that the V44M and V44A FAD mutations change the structure and dynamics of ε-cleavage sites. T48, the ε-cleavage site for Aβ42 generation, is likely more accessible to γ-secretase in the V44M and V44A mutants, leading to a shift towards the Aβ42 production line and to increased Aβ42/Aβ40 ratio. Such a structural mechanism may be applicable for other FAD mutants within APPTM and suggests that the ε-cleavage site may be a promising target for AD drug discovery.
Isotopically labelled compounds necessary for APPTM NMR sample production, such as 2H-labelled DPC, were purchased from Cambridge Isotope Laboratories.
Protein expression and purification
The APPTM gene was cloned into the pETM41 vector for expression as an MBP fusion protein and purified by an amylose affinity column followed by TEV protease digest32. The FAD mutants, V44M and V44A of APPTM was obtained through site-directed mutagenesis.
The NMR sample contains 0.2–0.5 mM of APPTM with 5% DPC, 25 mM sodium phosphate at pH 7.2 and 10% D2O. NMR experiments for assignment and structure calculation were performed on either a 600 or 800 MHz Bruker Advance II spectrometer equipped with cryogenic probes, at 313 K. Spectra were processed with nmrPipe software40 and analysed using Sparky (T.D. Goddard and D.G. Kneller, SPARKY 3, University of California, San Francisco, CA). For APPTM WT and V44M, the backbone resonances were assigned using HNCACB and HNCOCACB. Side-chain assignments were carried out using 15N-TOCSY, (H)C(CCO)NH-TOCSY, H(CCCO)NH-TOCSY and HC(C)H-TOCSY experiments. Stereospecific assignment of side-chain valine and leucine was obtained by fractional 10% 13C labelling. Assignments of ε-methyls of methionines were accomplished by mutagenesis. Backbone assignment of V44A was obtained by an HNCA experiment.
NMR structure determination
CYANA3.0 (ref. 41) was used for initial structure calculation. Distance constraints were obtained from 13C and 15N-NOESY spectra. Intermolecular NOEs were specifically detected by both filtered experiments and appropriate experiments for chimera NMR samples (Fig. 2). The structure from CYANA with the lowest target function values were subject to refinement using XPLOR-NIH42 with RDC from stretched gel43 and d(GpG)44. The quality of the final structures was assessed with PSVS45. 20 lowest energy conformers out of 200 refined structures were deposited into protein data bank (2LZ3 and 2LZ4). Ramanchandran statistics for the 20 structures are 95.2% and 95.1% in the most favoured regions, 4.8% and 4.9% in the additionally allowed regions for WT and V44M, respectively, 0% in either generally allowed or disallowed regions.
APPTM were exchanged into D2O using Zeba Spin Desalting Columns (Thermo Scientific). Samples were then monitored by 15N–1H HSQC for up to 30 h at pH 7.2 and 298 K.
How to cite this article: Chen, W. et al. Familial Alzheimer’s mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site. Nat. Commun. 5:3037 doi: 10.1038/ncomms4037 (2014).
Selkoe, D. J. Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N. Y. Acad. Sci. 924, 17–25 (2000).
Annaert, W. & De Strooper, B. A cell biological perspective on Alzheimer’s disease. Annu. Rev. Cell Dev. Biol. 18, 25–51 (2002).
Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
Burdick, D. et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546–554 (1992).
Zhang, Y., McLaughlin, R., Goodyer, C. & LeBlanc, A. Selective cytotoxicity of intracellular amyloid beta peptide(1-42) through p53 and Bax in cultured primary human neurons. J. Cell Biol. 156, 519–529 (2002).
Mucke, L. et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058 (2000).
De Jonghe, C. et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 10, 1665–1671 (2001).
Suzuki, N. et al. An increased percentage of long amyloid-beta protein secreted by familial amyloid-beta protein-precursor (Beta-App(717)) mutants. Science 264, 1336–1340 (1994).
Sinha, S. et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402, 537–540 (1999).
Vassar, R. et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741 (1999).
Fortini, M. E. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat. Rev. Mol. Cell Biol. 3, 673–684 (2002).
Fraering, P. C. et al. Purification and characterization of the human gamma-secretase complex. Biochemistry 43, 9774–9789 (2004).
Haass, C. Take five--BACE and the gamma-secretase quartet conduct Alzheimer’s amyloid beta-peptide generation. EMBO J. 23, 483–488 (2004).
Takami, M. et al. Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 29, 13042–13052 (2009).
Suzuki, N. et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336–1340 (1994).
Maruyama, K. et al. Familial Alzheimer’s disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43). Biochem. Biophys. Res. Commun. 227, 730–735 (1996).
Scheuner, D. et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat. Med. 2, 864–870 (1996).
Lichtenthaler, S. F. et al. Mechanism of the cleavage specificity of Alzheimer’s disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 96, 3053–3058 (1999).
Kumar-Singh, S. et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer’s disease. Hum. Mol. Genet. 9, 2589–2598 (2000).
Hecimovic, S. et al. Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol. Dis. 17, 205–218 (2004).
Ancolio, K. et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer’s disease. Proc. Natl Acad. Sci. USA 96, 4119–4124 (1999).
Yin, Y. I. et al. Gamma-secretase substrate concentration modulates the A beta 42/A beta 40 ratio. J. Biol. Chem. 282, 23639–23644 (2007).
Barrett, P. J. et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336, 1168–1171 (2012).
Beel, A. J. et al. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry 47, 9428–9446 (2008).
Kienlen-Campard, P. et al. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J. Biol. Chem. 283, 7733–7744 (2008).
Gorman, P. M. et al. Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer’s disease mutants. BMC Neurosci. 9, 17 (2008).
Sato, T. et al. A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc. Natl Acad. Sci. USA 106, 1421–1426 (2009).
Nadezhdin, K. D., Bocharova, O. V., Bocharov, E. V. & Arseniev, A. S. Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment. FEBS Lett. 586, 1687–1692 (2012).
Lu, J. X., Yau, W. M. & Tycko, R. Evidence from solid-state NMR for nonhelical conformations in the transmembrane domain of the amyloid precursor protein. Biophys. J. 100, 711–719 (2011).
Miyashita, N., Straub, J. E., Thirumalai, D. & Sugita, Y. Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations. J. Am. Chem. Soc. 131, 3438–3439 (2009).
Wang, H. et al. Molecular determinants and thermodynamics of the amyloid precursor protein transmembrane domain implicated in Alzheimer's disease. J. Mol. Biol. 408, 879–895 (2011).
Chen, W., Gamache, E., Richardson, D., Du, Z. M. & Wang, C. Y. Expression, purification, and reconstitution of the transmembrane domain of the human amyloid precursor protein for NMR studies. Protein. Expr. Purif. 81, 11–17 (2012).
MacKenzie, K. R., Prestegard, J. H. & Engelman, D. M. A transmembrane helix dimer: structure and implications. Science 276, 131–133 (1997).
Dimitrov, M. et al. Alzheimer’s disease mutations in APP but not gamma-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat. Commun. 4, 2246 (2013).
Chavez-Gutierrez, L. et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 31, 2261–2274 (2012).
Golde, T. E., Ran, Y. & Felsenstein, K. M. Shifting a complex debate on gamma-secretase cleavage and Alzheimer’s disease. EMBO J. 31, 2237–2239 (2012).
Botev, A. et al. The amyloid precursor protein C-terminal fragment C100 occurs in monomeric and dimeric stable conformations and binds gamma-secretase modulators. Biochemistry 50, 828–835 (2011).
Munter, L. M. et al. Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J. Biol. Chem. 285, 21636–21643 (2010).
Munter, L. M. et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J. 26, 1702–1712 (2007).
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
Guntert, P. Automated NMR structure calculation with CYANA. Methods Mol. Biol. 278, 353–378 (2004).
Schwieters, C. D., Kuszewski, J. J., Tjandra, N. & Clore, G. M. The Xplor-NIH NMR molecular structure determination package. J. Magn. Res. 160, 66–74 (2003).
Chou, J. J., Gaemers, S., Howder, B., Louis, J. M. & Bax, A. A simple apparatus for generating stretched polyacrylamide gels, yielding uniform alignment of proteins and detergent micelles. J. Biomol. NMR 21, 377–382 (2001).
Lorieau, J., Yao, L. & Bax, A. Liquid crystalline phase of G-tetrad DNA for NMR study of detergent-solubilized proteins. J. Am. Chem. Soc. 130, 7536–7537 (2008).
Bhattacharya, A., Tejero, R. & Montelione, G. T. Evaluating protein structures determined by structural genomics consortia. Proteins 66, 778–795 (2007).
This work has been partially supported by AHAF grant A2009340 to C.W.
The authors declare no competing financial interests.
About this article
Cite this article
Chen, W., Gamache, E., Rosenman, D. et al. Familial Alzheimer’s mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site. Nat Commun 5, 3037 (2014). https://doi.org/10.1038/ncomms4037
This article is cited by
Nature Protocols (2019)
Increased H-Bond Stability Relates to Altered ε-Cleavage Efficiency and Aβ Levels in the I45T Familial Alzheimer’s Disease Mutant of APP
Scientific Reports (2019)
Cellular and Molecular Life Sciences (2019)
Coupled Transmembrane Substrate Docking and Helical Unwinding in Intramembrane Proteolysis of Amyloid Precursor Protein
Scientific Reports (2018)
Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
Acta Neuropathologica Communications (2016)